Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak płuca wczesnego stadium (IA3 lub IB), usunięty chirurgicznie w całości (bez pozostawienia komórek rakowych).
- •Operacja usunięcia płata płuca lub większa. W niektórych przypadkach dopuszczalna jest mniejsza operacja, jeśli guz był mały.
- •Wykonano odpowiednie badania węzłów chłonnych.
- •W badaniu markera PD-L1 na komórkach rakowych uzyskano wynik 50% lub wyższy.
- •Nie stwierdzono określonych mutacji genetycznych (EGFR, ALK) w komórkach raka.
- •Pacjent został zakwalifikowany do badania od 3 do 11 tygodni po operacji.
- •Pacjent doszedł do siebie po operacji.
✗ Disqualifies
- •Rak płuca zawierający komórki drobnokomórkowe.
- •Obecność określonych mutacji w genie EGFR lub ALK (chyba że rak jest czysto płaskonabłonkowy).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (83)
Tower Cancer Research Foundation
Beverly Hills, United States
Cedars-Sinai Medical Center
Los Angeles, United States
Cedars-Sinai Cancer - Tarzana
Tarzana, United States
Torrance Memorial Physician Network - Cancer Care
Torrance, United States
Beebe South Coastal Health Campus
Millville, United States
Helen F Graham Cancer Center
Newark, United States
Medical Oncology Hematology Consultants PA
Newark, United States
Beebe Health Campus
Rehoboth Beach, United States
Kootenai Health - Coeur d'Alene
Coeur d'Alene, United States
Kootenai Clinic Cancer Services - Post Falls
Post Falls, United States
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, United States
Illinois CancerCare-Bloomington
Bloomington, United States
Illinois CancerCare-Canton
Canton, United States
Illinois CancerCare-Carthage
Carthage, United States
Carle at The Riverfront
Danville, United States
Cancer Care Specialists of Illinois - Decatur
Decatur, United States
Decatur Memorial Hospital
Decatur, United States
Carle Physician Group-Effingham
Effingham, United States
Illinois CancerCare-Eureka
Eureka, United States
Illinois CancerCare-Galesburg
Galesburg, United States
Illinois CancerCare-Kewanee Clinic
Kewanee, United States
Illinois CancerCare-Macomb
Macomb, United States
Carle Physician Group-Mattoon/Charleston
Mattoon, United States
Carle BroMenn Medical Center
Normal, United States
Carle Cancer Institute Normal
Normal, United States
Cancer Care Center of O'Fallon
O'Fallon, United States
HSHS Saint Elizabeth's Hospital
O'Fallon, United States
Illinois CancerCare-Ottawa Clinic
Ottawa, United States
Illinois CancerCare-Pekin
Pekin, United States
Illinois CancerCare-Peoria
Peoria, United States
Illinois CancerCare-Peru
Peru, United States
Illinois CancerCare-Princeton
Princeton, United States
Southern Illinois University School of Medicine
Springfield, United States
Springfield Clinic
Springfield, United States
Springfield Memorial Hospital
Springfield, United States
Carle Cancer Center
Urbana, United States
Illinois CancerCare - Washington
Washington, United States
Northwest Cancer Center - Crown Point
Crown Point, United States
Northwest Oncology LLC
Dyer, United States
Saint Mary Medical Center
Hobart, United States
Saint Catherine Hospital
Indianapolis, United States
The Community Hospital
Munster, United States
Women's Diagnostic Center - Munster
Munster, United States
Northwest Cancer Center - Valparaiso
Valparaiso, United States
Mary Greeley Medical Center
Ames, United States
McFarland Clinic - Ames
Ames, United States
Physicians' Clinic of Iowa PC
Cedar Rapids, United States
Mercy Hospital
Cedar Rapids, United States
Oncology Associates at Mercy Medical Center
Cedar Rapids, United States
McFarland Clinic - Trinity Cancer Center
Fort Dodge, United States
McFarland Clinic - Marshalltown
Marshalltown, United States
Owensboro Health Mitchell Memorial Cancer Center
Owensboro, United States
Bronson Battle Creek
Battle Creek, United States
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Grand Rapids, United States
Bronson Methodist Hospital
Kalamazoo, United States
West Michigan Cancer Center
Kalamazoo, United States
Corewell Health Lakeland Hospitals - Niles Hospital
Niles, United States
Corewell Health Reed City Hospital
Reed City, United States
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
Saint Joseph, United States
Corewell Health Lakeland Hospitals - Saint Joseph Hospital
Saint Joseph, United States
Munson Medical Center
Traverse City, United States
University of Michigan Health - West
Wyoming, United States
Saint Francis Medical Center
Cape Girardeau, United States
Billings Clinic Cancer Center
Billings, United States
Bozeman Health Deaconess Hospital
Bozeman, United States
Benefis Sletten Cancer Institute
Great Falls, United States
Community Medical Center
Missoula, United States
Ocean University Medical Center
Brick, United States
Southern Ocean County Medical Center
Manahawkin, United States
Jersey Shore Medical Center
Neptune City, United States
Riverview Medical Center/Booker Cancer Center
Red Bank, United States
Hematology Oncology Associates of CNY at Camillus
Camillus, United States
Hematology Oncology Associates of Central New York-East Syracuse
East Syracuse, United States
Stony Brook University Medical Center
Stony Brook, United States
FirstHealth of the Carolinas-Moore Regional Hospital
Pinehurst, United States
ProMedica Flower Hospital
Sylvania, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
Bellin Memorial Hospital
Green Bay, United States
Froedtert Menomonee Falls Hospital
Menomonee Falls, United States
ProHealth D N Greenwald Center
Mukwonago, United States
ProHealth Oconomowoc Memorial Hospital
Oconomowoc, United States
ProHealth Waukesha Memorial Hospital
Waukesha, United States
UW Cancer Center at ProHealth Care
Waukesha, United States
Trial contact
Site Public Contact
Kamya Sankar
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Gregory A. Masters
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
John M. Schallenkamp
PRINCIPAL_INVESTIGATOR
Site Public Contact
Bryan A. Faller
PRINCIPAL_INVESTIGATOR
Site Public Contact
Vamsi K. Vasireddy
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Joseph J. Merchant
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Bharat Jenigiri
PRINCIPAL_INVESTIGATOR
Site Public Contact
Deborah W. Wilbur
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Jewraj G. Maheshwari
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kathleen Y. Butler
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Rachel E. NeMoyer
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Steven M. Duffy
PRINCIPAL_INVESTIGATOR
Site Public Contact
Amna Sher
PRINCIPAL_INVESTIGATOR
Site Public Contact
Charles S. Kuzma
PRINCIPAL_INVESTIGATOR
Site Public Contact
Ali Raufi
PRINCIPAL_INVESTIGATOR
Site Public Contact
Muhammad Furqan
PRINCIPAL_INVESTIGATOR
Site Public Contact
Srinandan Guntupalli
PRINCIPAL_INVESTIGATOR
Site Public Contact
Hui-Zi Chen
PRINCIPAL_INVESTIGATOR
Site Public Contact
Timothy R. Wassenaar
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.